Serious Adverse Events in Oncology Trials: Novel Risk Assessment and Management Approaches

Serious adverse events (SAEs) remain a critical concern in oncology clinical trials, directly impacting patient safety and the development of new therapies. With the growing use of targeted treatments and immunotherapies, treatment-related toxicities have become more complex and less predictable than with conventional chemotherapy. Traditional reactive approaches are increasingly inadequate, necessitating proactive strategies for early identification and management of SAEs. Advances in artificial intelligence (AI) and predictive analytics have enabled the early detection of adverse events and the identification of high-risk patients (6,7,20). Additionally, decentralized trials and wearable technologies now allow continuous, real-world patient monitoring (16). Despite these innovations, challenges such as data quality, algorithm transparency, and evolving regulatory frameworks limit their widespread adoption. This review synthesizes current knowledge on SAE risk factors, discusses monitoring and management strategies, and highlights emerging technologies aimed at enhancing patient safety in oncology trials.

Serious Adverse Events, Oncology Trials, Risk Assessment

1. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of lymphoma. J Clin Oncol. 2018;36(12):1234–1242. doi:10.1200/JCO.2017.74.0470 [Google Scholar] [Crossref]

2. U.S. Food and Drug Administration. Guidance for Industry: Clinical Trial Safety Reporting. Silver Spring (MD): FDA; 2020. Available from: https://www.fda.gov/media/116778/download [Google Scholar] [Crossref]

3. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Cancer Treat Rev. 2017;55:1–10. doi:10.1016/j.ctrv.2016.12.001 [Google Scholar] [Crossref]

4. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. doi:10.1056/NEJMra1703481 [Google Scholar] [Crossref]

5. Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, et al. Compressing drug development timelines in oncology. Clin Cancer Res. 2019;25(18):5641–5649. doi:10.1158/1078-0432.CCR-18-1232 [Google Scholar] [Crossref]

6. Beam AL, Kohane IS. Big data and machine learning in health care. JAMA. 2018;319(13):1317–1318. doi:10.1001/jama.2017.18391 [Google Scholar] [Crossref]

7. Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56. doi:10.1038/s41591-018-0300-7 [Google Scholar] [Crossref]

8. Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. Lancet Oncol. 2019;20(6):e324. doi:10.1016/S1470-2045(19)30119-0 [Google Scholar] [Crossref]

9. Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, Picci P, et al. Canine tumor models for the study of cancer biology and treatment. Clin Pharmacol Ther. 2015;97(5):467–474. doi:10.1002/cpt.95 [Google Scholar] [Crossref]

10. Ioannidis JPA. Adverse events in randomized trials: Neglected, restricted, distorted, and silenced. BMJ. 2017;356:j408. doi:10.1136/bmj.j408 [Google Scholar] [Crossref]

11. Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis CA, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318(2):197–198. doi:10.1001/jama.2017.7156 [Google Scholar] [Crossref]

12. Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Lancet Oncol. 2015;16(10):e504–e504. doi:10.1016/S1470-2045(15)00158-1 [Google Scholar] [Crossref]

13. Rowinsky EK. The current and future role of cytotoxic chemotherapy in oncology practice. Semin Oncol. 2016;43(4):555–563. doi:10.1053/j.seminoncol.2016.06.002 [Google Scholar] [Crossref]

14. Temple R. Meta-analysis and the evaluation of adverse effects. N Engl J Med. 2011;364(2):125–133. doi:10.1056/NEJMra1009413 [Google Scholar] [Crossref]

15. U.S. Food and Drug Administration. Guidance for Industry: Oversight of Clinical Investigations—A Risk-Based Approach to Monitoring. Silver Spring (MD): FDA; 2013. Available from: https://www.fda.gov/media/86164/download [Google Scholar] [Crossref]

16. Sirintrapun SJ, Lopez AM. Telemedicine in cancer care. J Oncol Pract. 2018;14(10):612–618. doi:10.1200/JOP.18.00125 [Google Scholar] [Crossref]

17. Postow MA, Hellmann MD. Management of immune-related adverse events associated with immune checkpoint inhibitors. N Engl J Med. 2018;378(2):158–168. doi:10.1056/NEJMra1703481 [Google Scholar] [Crossref]

18. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2007;17(3):159–166. doi:10.1016/j.semradonc.2007.04.001 [Google Scholar] [Crossref]

19. London AJ. Ethical issues in clinical research and adverse event reporting. Hastings Cent Rep. 2019;49(2):17–24. doi:10.1002/hast.990 [Google Scholar] [Crossref]

20. Wiens J, Saria S, Sendak M, Ghassemi M, Liu VX, Doshi-Velez F, et al. Do no harm: A roadmap for responsible machine learning in healthcare. Nat Med. 2019;25(1):30–36. doi:10.1038/s41591-018-0316-8 [Google Scholar] [Crossref]

• Evaluation of C-Peptide in Breast Cancer Patients in Anambra State, Nigeria